Path for Embattled Breast Cancer Drugs Cleared by One Protein Inhibitor

More than 60% of breast cancers harbor genomic changes in the PI3K-AKT-mTOR, or phosphatidylinositol-3-kinase/AKT/mechanistic target of rapamycin, pathway, but attempts to develop drugs that target components in the pathway have been largely unsuccessful. Potentially hundreds of clinical trials have failed, but scientists haven’t really understood why. Researchers headed by a team at the University of California, San Francisco (UCSF), have now used a new unbiased chemoproteomics technique